Medical prevention of stroke and stroke recurrence in patients with TIA and minor stroke
- PMID: 19558342
- DOI: 10.1517/14656560903048934
Medical prevention of stroke and stroke recurrence in patients with TIA and minor stroke
Abstract
Background: Secondary stroke prevention after transient ischemic stroke (TIA) or minor stroke is of major importance in order to avoid recurrent cerebrovascular events and decrease morbidity and mortality.
Objective/methods: Systematically review of recently published, high-quality studies emphasizing the need for emergency assessment and treatment of patients with TIA and minor stroke and to give a comprehensive and distinct overview over medical secondary stroke prevention trials performed in these patients.
Results/conclusions: Evaluation and implementation of preventive stroke therapy has to be immediate in patients with TIA and stroke. For patients with non-cardioembolic stroke, antiplatelet agents are the treatment of choice. Aspirin plus extended-release dipyridamole and clopidogrel are more effective than aspirin and should be used in patients with a high risk of recurrent stroke. Oral anticoagulation is highly effective in patients with a cardiac source of embolism. Treatment of risk factors such as arterial hypertension and high cholesterol is even more important in secondary stroke prevention than in primary prevention. Vitamin supplementation and lowering of elevated levels of homocysteine are not effective in stroke prevention.
Similar articles
-
Antiplatelet therapy for the prevention of recurrent stroke and other serious vascular events: a review of the clinical trial data and guidelines.Curr Med Res Opin. 2007 Jun;23(6):1453-62. doi: 10.1185/030079907X199727. Epub 2007 May 17. Curr Med Res Opin. 2007. PMID: 17559741 Review.
-
Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected].Int J Clin Pract. 2007 Oct;61(10):1739-48. doi: 10.1111/j.1742-1241.2007.01515.x. Int J Clin Pract. 2007. PMID: 17877660 Review.
-
Combination antiplatelet agents for secondary prevention of ischemic stroke.Pharmacotherapy. 2008 Oct;28(10):1233-42. doi: 10.1592/phco.28.10.1233. Pharmacotherapy. 2008. PMID: 18823219 Review.
-
Antiplatelet agents and randomized trials.Rev Neurol Dis. 2007 Fall;4(4):177-83. Rev Neurol Dis. 2007. PMID: 18195669 Review.
-
Secondary stroke prevention with antiplatelet drugs: have we reached the ceiling?Int J Stroke. 2006 Feb;1(1):4-8. doi: 10.1111/j.1747-4949.2005.00016.x. Int J Stroke. 2006. PMID: 18706062
Cited by
-
Clinical neuroprotective drugs for treatment and prevention of stroke.Int J Mol Sci. 2012;13(6):7739-7761. doi: 10.3390/ijms13067739. Epub 2012 Jun 21. Int J Mol Sci. 2012. PMID: 22837724 Free PMC article. Review.
-
Dipyridamole increases gap junction coupling in bovine GM-7373 aortic endothelial cells by a cAMP-protein kinase A dependent pathway.J Bioenerg Biomembr. 2010 Feb;42(1):79-84. doi: 10.1007/s10863-009-9262-2. Epub 2010 Jan 7. J Bioenerg Biomembr. 2010. PMID: 20054624
-
Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival.Oncotarget. 2010 Nov;1(7):628-638. doi: 10.18632/oncotarget.197. Oncotarget. 2010. PMID: 21317458 Free PMC article.
-
[Antithrombotic and anticoagulation therapy after stroke and transient ischemic attacks].Nervenarzt. 2010 Dec;81(12):1509-17; quiz 1518-9. doi: 10.1007/s00115-010-3133-2. Nervenarzt. 2010. PMID: 21181335 German.
-
Secondary prevention of stroke: Pleiotropic effects of optimal oral pharmacotherapy.Exp Ther Med. 2012 Jul;4(1):3-7. doi: 10.3892/etm.2012.560. Epub 2012 Apr 24. Exp Ther Med. 2012. PMID: 23060914 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical